Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Retained Earnings: 2022-2024

Historic Retained Earnings for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to -$490.8 million.

  • Stoke Therapeutics' Retained Earnings rose 8.45% to -$439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$439.8 million, marking a year-over-year increase of 8.45%. This contributed to the annual value of -$490.8 million for FY2024, which is 22.14% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Retained Earnings of -$490.8 million as of FY2024, which was down 22.14% from -$401.8 million recorded in FY2023.
  • Stoke Therapeutics' 5-year Retained Earnings high stood at -$297.1 million for FY2022, and its period low was -$490.8 million during FY2024.
  • For the 3-year period, Stoke Therapeutics' Retained Earnings averaged around -$396.6 million, with its median value being -$401.8 million (2023).
  • Data for Stoke Therapeutics' Retained Earnings shows a maximum YoY plummeted of 35.23% (in 2023) over the last 5 years.
  • Over the past 3 years, Stoke Therapeutics' Retained Earnings (Yearly) stood at -$297.1 million in 2022, then plummeted by 35.23% to -$401.8 million in 2023, then declined by 22.14% to -$490.8 million in 2024.